Preventive and alleviative effects of the dual enkephalinase inhibitor (Denki) PL265 in a murine model of neuropathic pain.
Neuropathic pain remains difficult to treat due to the involvement of various pathophysiological mechanisms in its pathogeny. Among the different opioidergic systems the enkephalinergic one is primarily recruited via activation of delta opioid receptor (DOP) in chronic pain and of mu opioid receptor (MOP) in acute pain. To investigate the role of their endogenous ligands Met and Leu-enkephalin in neuropathic pain control, a dual inhibitor of their degrading enzymes, PL265, which acts restrictively at the level of peripheral nociceptors, was administered per os to assess its efficacy in pain prevention and alleviation using a partial sciatic nerve ligation model (PSNL) in mice. We demonstrated here that the pre-injury oral administration of PL265 (50mg/kg) during the 9 days of neuropathy development reduces thermal hyperalgesia and mechanical allodynia for two weeks after the end of treatment. The repeated administration (50mg/kg daily, during 10 days) does not induce tolerance. Therefore, protecting the enkephalins released at the peripheral level during neuropathic pain with oral PL265 seems to be a promising approach to prevent and alleviate the painful symptoms of neuropathic pain in humans without the unwanted effects of exogenous opiates such as morphine.
Pharmaleads, Paris BioPark, 11 rue Watt, 75013 Paris, France.
Elisabeth
E
Bonnard
Pharmaleads, Paris BioPark, 11 rue Watt, 75013 Paris, France.
Hervé
H
Poras
Pharmaleads, Paris BioPark, 11 rue Watt, 75013 Paris, France.
Marie-Claude
MC
Fournié-Zaluski
Pharmaleads, Paris BioPark, 11 rue Watt, 75013 Paris, France; Université Paris-Descartes, 4 Avenue de l'Observatoire, 75006 Paris, France. Electronic address: bernard.roques@pharmaleads.com.
Bernard P
BP
Roques
D000409:Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001835:Body Weight / Q000187:drug effects; D004195:Disease Models, Animal; D006930:Hyperalgesia / Q000517:prevention & control; D008297:Male; D051379:Mice; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D009437:Neuralgia / Q000178:diet therapy* / Q000201:enzymology / Q000517:prevention & control*; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D012449:Safety; D013997:Time Factors; D014110:Touch / Q000187:drug effects
D001713:Biphenyl Compounds; C000602480:N-(3-((1-aminoethyl)(hydroxy)phosphoryl)-2-(1,1'-biphenyl-4-ylmethyl)propanoyl)alanine; D011480:Protease Inhibitors; D015260:Neprilysin; D000409:Alanine
Dual enkephalinase inhibitor; Endogenous enkephalins; Neuropathic pain; Prevention; Tolerance